Replimune Group (NASDAQ:REPL) Stock Price Down 3.4%

Replimune Group, Inc. (NASDAQ:REPL)’s share price traded down 3.4% on Tuesday . The company traded as low as $8.97 and last traded at $9.04. 46,156 shares changed hands during mid-day trading, a decline of 97% from the average session volume of 1,332,680 shares. The stock had previously closed at $9.36.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. HC Wainwright lifted their price objective on shares of Replimune Group from $12.00 to $17.00 and gave the company a “buy” rating in a research note on Friday, June 7th. Wedbush restated an “outperform” rating and set a $16.00 price target on shares of Replimune Group in a research report on Thursday, June 6th. Finally, Barclays boosted their price target on shares of Replimune Group from $13.00 to $17.00 and gave the company an “overweight” rating in a research report on Friday, June 7th.

Replimune Group Stock Down 7.3 %

The business’s 50-day moving average price is $6.95 and its 200 day moving average price is $7.62. The company has a current ratio of 10.72, a quick ratio of 10.72 and a debt-to-equity ratio of 0.18.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Thursday, May 16th. The company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.04. Sell-side analysts forecast that Replimune Group, Inc. will post -3.31 EPS for the current fiscal year.

Insider Transactions at Replimune Group

In other Replimune Group news, Chairman Philip Astley-Sparke sold 37,928 shares of the business’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $6.47, for a total value of $245,394.16. Following the completion of the sale, the chairman now directly owns 1,487,350 shares of the company’s stock, valued at $9,623,154.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Replimune Group news, Chairman Philip Astley-Sparke sold 37,928 shares of the business’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $6.47, for a total value of $245,394.16. Following the completion of the sale, the chairman now directly owns 1,487,350 shares of the company’s stock, valued at $9,623,154.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Sushil Patel sold 20,194 shares of the business’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $6.47, for a total transaction of $130,655.18. Following the completion of the sale, the chief executive officer now directly owns 212,014 shares of the company’s stock, valued at $1,371,730.58. The disclosure for this sale can be found here. In the last ninety days, insiders sold 107,598 shares of company stock valued at $712,516. Insiders own 20.60% of the company’s stock.

Hedge Funds Weigh In On Replimune Group

Several hedge funds and other institutional investors have recently modified their holdings of REPL. Tower Research Capital LLC TRC increased its position in shares of Replimune Group by 236.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,207 shares of the company’s stock valued at $35,000 after buying an additional 2,958 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in Replimune Group by 352.8% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,833 shares of the company’s stock worth $58,000 after purchasing an additional 5,324 shares during the period. Exchange Traded Concepts LLC grew its holdings in Replimune Group by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 7,837 shares of the company’s stock worth $66,000 after purchasing an additional 1,988 shares during the period. Quest Partners LLC bought a new position in shares of Replimune Group during the fourth quarter valued at approximately $76,000. Finally, Diversified Trust Co purchased a new position in shares of Replimune Group during the first quarter valued at approximately $94,000. 92.53% of the stock is owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.